Assignee
IMMUNOCORE LTD
GB·35 granted patents·95 pending applications·418 citations·filing 2003–2025
Top patents by PatentIndex Score
130 records- 0196US8361794B2Cells expressing a modified T cell receptorIMMUNOCORE LTD·Filed 2005·Granted Jan 29, 2013·47 cites·25 claims
- 0295US8367804B2High affinity NY-ESO T cell receptorsIMMUNOCORE LTD·Filed 2011·Granted Feb 5, 2013·20 cites·4 claims
- 0394US8008438B2High affinity NY-ESO T cell receptorsIMMUNOCORE LTD·Filed 2010·Granted Aug 30, 2011·11 cites·2 claims
- 0494US7608410B2Method of improving T cell receptorsIMMUNOCORE LTD·Filed 2008·Granted Oct 27, 2009·51 cites·13 claims
- 0593US11427624B2T cell receptorsIMMUNOCORE LTD·Filed 2021·Granted Aug 30, 2022·11 cites·11 claims
- 0693US7763718B2Soluble T cell receptorsIMMUNOCORE LTD·Filed 2007·Granted Jul 27, 2010·33 cites·9 claims
- 0793US7666604B2Modified soluble T cell receptorIMMUNOCORE LTD·Filed 2003·Granted Feb 23, 2010·77 cites·19 claims
- 0893US7569664B2Single chain recombinant T cell receptorsIMMUNOCORE LTD·Filed 2003·Granted Aug 4, 2009·78 cites·27 claims
- 0992US10517960B2Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2019·Granted Dec 31, 2019·9 cites·6 claims
- 1089US12018062B2T cell receptorsIMMUNOCORE LTD·Filed 2023·Granted Jun 25, 2024·1 cites·22 claims
- 1189US9068178B2Nucleic acid molecules encoding non-naturally occurring T cell receptors and cells thereofIMMUNOCORE LTD·Filed 2013·Granted Jun 30, 2015·11 cites·66 claims
- 1288US9255135B2High affinity HIV T cell receptorsIMMUNOCORE LTD·Filed 2013·Granted Feb 9, 2016·5 cites·19 claims
- 1387US12134647B2Binding moleculesIMMUNOCORE LTD·Filed 2024·Granted Nov 5, 2024·3 cites·22 claims
- 1487US11017882B2Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complexIMMUNOCORE LTD·Filed 2015·Granted May 25, 2021·6 cites·13 claims
- 1587US8378074B2High affinity HIV T cell receptorsIMMUNOCORE LTD·Filed 2006·Granted Feb 19, 2013·9 cites·24 claims
- 1686US11505590B2T cell receptorsIMMUNOCORE LTD·Filed 2017·Granted Nov 22, 2022·10 cites·45 claims
- 1785US12065475B2T cell receptors and fusion proteins thereofIMMUNOCORE LTD·Filed 2023·Granted Aug 20, 2024·3 cites·21 claims
- 1885US11718657B2T cell receptorsIMMUNOCORE LTD·Filed 2018·Granted Aug 8, 2023·4 cites·17 claims
- 1984US12195534B2Binding moleculesIMMUNOCORE LTD·Filed 2024·Granted Jan 14, 2025·2 cites·22 claims
- 2084US11929151B2Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complexIMMUNOCORE LTD·Filed 2021·Granted Mar 12, 2024·1 cites·13 claims
- 2184US8017730B2T cell receptors which specifically bind to VYGFVRACL-HLA-A24IMMUNOCORE LTD·Filed 2006·Granted Sep 13, 2011·5 cites·1 claims
- 2283US10576162B2Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2019·Granted Mar 3, 2020·2 cites·2 claims
- 2383US9115372B2Cells expressing modified T cell receptorIMMUNOCORE LTD·Filed 2012·Granted Aug 25, 2015·5 cites·20 claims
- 2481US12103971B2HIV specific binding moleculesIMMUNOCORE LTD·Filed 2022·Granted Oct 1, 2024·2 cites·16 claims
- 2581US2023241238A1Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 2680US2024368243A1T Cell ReceptorsIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 2780US2024312566A1Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complexIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 2879US10420846B2Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2019·Granted Sep 24, 2019·1 cites·5 claims
- 2978US11639374B2T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complexIMMUNOCORE LTD·Filed 2016·Granted May 2, 2023·6 cites·14 claims
- 3078US2025134956A1Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc moleculesIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 3175US11440944B2Engineered immune-mobilizing T-cell receptors with enhanced affinity for HIV-1 GagIMMUNOCORE LTD·Filed 2017·Granted Sep 13, 2022·1 cites·10 claims
- 3274US11827688B2Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion proteinIMMUNOCORE LTD·Filed 2017·Granted Nov 28, 2023·2 cites·14 claims
- 3373US10835577B2Peptides derived from Kita-kyushu lung cancer antigen (KKLC1, CT83, CXorf61) and complexes comprising such peptides bound to MHC moleculesIMMUNOCORE LTD·Filed 2016·Granted Nov 17, 2020·1 cites·10 claims
- 3470US2023330181A1Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc moleculesIMMUNOCORE LTD·Filed 2023·Application pending·0 cites
- 3569US2025026829A1Binding moleculesIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 3667US2023192806A1Engineered immune-mobilizing t-cell receptors with enhanced affinity for hiv-1 gagIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 3766US2024052011A1Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion proteinIMMUNOCORE LTD·Filed 2023·Application pending·0 cites
- 3866US2025179178A1Binding moleculesIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 3966US2022235113A1TCR LibrariesIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 4066US2024301027A1Treatment of mage-a4 positive cancerIMMUNOCORE LTD·Filed 2024·Application pending·0 cites
- 4165US10851366B2Peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to MHC moleculesIMMUNOCORE LTD·Filed 2016·Granted Dec 1, 2020·1 cites·10 claims
- 4264US2019247512A1Bifunctional polypeptidesIMMUNOCORE LTD·Filed 2018·Application pending·0 cites
- 4363US2024092859A1T cell receptors and fusion proteins thereofIMMUNOCORE LTD·Filed 2023·Application pending·0 cites
- 4463US2021371493A1Tcr librariesIMMUNOCORE LTD·Filed 2021·Application pending·0 cites
- 4563US2023190901A1Peptides derived from melanoma-associated antigen c2 (magec2) and uses thereofIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 4662US2021061874A1Claudin-6 peptidesIMMUNOCORE LTD·Filed 2020·Application pending·0 cites
- 4761US2021121526A1Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc moleculesIMMUNOCORE LTD·Filed 2020·Application pending·0 cites
- 4861US2021322528A1Peptides from npsr1IMMUNOCORE LTD·Filed 2021·Application pending·0 cites
- 4960US2025333504A1TreatmentIMMUNOCORE LTD·Filed 2022·Application pending·0 cites
- 5058US11739441B2TCR librariesIMMUNOCORE LTD·Filed 2021·Granted Aug 29, 2023·0 cites·1 claims
Showing the top 50 of 130 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →